United States: FDA To Review Vertex Pharmaceutical's Application For CRISPR-Based Gene Therapy Exa-Cel - Goodwin Procter LLP

United States: FDA To Review Vertex Pharmaceutical's Application For CRISPR-Based Gene Therapy Exa-Cel - Goodwin Procter LLP

Mondaq

Published

The Cellular, Tissue, and Gene Therapies Advisory Committee of the FDA is meeting tomorrow, Tuesday, October 31, 2023, to review a Biologics License Application by Vertex Pharmaceuticals Inc. for exagamglogene autotemcel (exa-cel).

Full Article